
Improving Dialysis Patient Outcomes Under the ESRD QIP: The Impact of Timely Medication Reconciliation

INTERVENTION: Beginning in 2020, the End-Stage Renal Disease Quality Incentive Program (ESRD QIP) added a reporting measure to track monthly dialysis facility performance of MEDICATION RECONCILIATION (MedRec), a formalized process where healthcare professionals compare a patient's prescribed and actual medication regimen, for each beneficiary in their care.

Result 1: No difference in hospitalization trends between dialysis facilities with high (>90%) and low MedRec (<90%) compliance



*2020 excludes January through June due to COVID-19 Public Health Emergency

Authors: Jillian Schrager, MPH¹, Alissa Kapke, MS¹, Jeffrey Pearson, MS¹, Eric Young, MD¹, Dominick Esposito, PhD²

¹ Arbor Research Collaborative for Health ² Westat Insight

GOAL: To reduce the frequency of medication-related problems among patients with ESRD, including unnecessary medical encounters such as hospitalizations.

2021

Result 2: Reduced risk of hospitalization for patients with more recent MedRec: risk of hospitalization more than doubles after one month since MedRec

Days Since Last MedRec
1 to 14 (reference group)
15 to 30 vs. 1 to 14
31 to 45 vs. 1 to 14
46 or more vs. 1 to 14



Unlocking the Power of Evidence for Better Health

Relative Risk of Hospitalization


1.00

1.42**


2.38**

3.15**

** Statistically significant, p<0.05



Quintiles: Facility percent of index hospitalizations with MedRec within 7 days post-discharge



Result 3: Reduced risk of unplanned 30-day *readmission* at dialysis facilities with the most MedRecs

performed within one week of hospital discharge

Disclaimer: This material was prepared by Arbor Research Collaborative for Health and Westat, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Contract GS-10F-0136X/75FCMC21F0090, Jan. 10, 2024